Envision Healthcare (NYSE:EVHC) received a $40.00 price target from stock analysts at SunTrust Banks in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. SunTrust Banks’ price target would suggest a potential upside of 15.87% from the stock’s previous close.
Several other equities analysts have also weighed in on the stock. Jefferies Group set a $71.00 price objective on shares of Envision Healthcare and gave the company a “buy” rating in a report on Wednesday, November 1st. KeyCorp set a $67.00 price objective on shares of Envision Healthcare and gave the company a “buy” rating in a report on Wednesday, November 1st. Cantor Fitzgerald restated a “hold” rating and issued a $30.00 price objective on shares of Envision Healthcare in a report on Tuesday, November 14th. Canaccord Genuity restated a “buy” rating and issued a $32.00 price objective (down from $68.00) on shares of Envision Healthcare in a report on Thursday, November 2nd. Finally, Bank of America cut their price objective on shares of Envision Healthcare from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $43.25.
Envision Healthcare (NYSE:EVHC) opened at $34.52 on Thursday. Envision Healthcare has a 12-month low of $23.77 and a 12-month high of $73.00. The stock has a market cap of $3,943.41, a P/E ratio of 10.07, a PEG ratio of 1.06 and a beta of 0.57. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.01.
Envision Healthcare announced that its Board of Directors has approved a stock buyback plan on Monday, September 18th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to reacquire up to 4.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Envision Healthcare by 1.8% in the second quarter. Vanguard Group Inc. now owns 11,471,402 shares of the company’s stock valued at $718,912,000 after purchasing an additional 204,584 shares in the last quarter. BlackRock Inc. increased its stake in Envision Healthcare by 2.1% in the second quarter. BlackRock Inc. now owns 7,345,283 shares of the company’s stock valued at $460,330,000 after purchasing an additional 147,652 shares in the last quarter. Maverick Capital Ltd. increased its stake in Envision Healthcare by 66.2% in the second quarter. Maverick Capital Ltd. now owns 5,093,292 shares of the company’s stock valued at $319,197,000 after purchasing an additional 2,028,026 shares in the last quarter. Janus Henderson Group PLC increased its stake in Envision Healthcare by 0.3% in the third quarter. Janus Henderson Group PLC now owns 3,958,329 shares of the company’s stock valued at $177,927,000 after purchasing an additional 13,242 shares in the last quarter. Finally, OZ Management LP bought a new stake in Envision Healthcare in the third quarter valued at approximately $131,987,000.
About Envision Healthcare
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.